Branimir Sikic, MD

Branimir Sikic, MD

Hematology Stanford, CA

Professor, Medicine - Oncology, Stanford University Medical Center


Office Address

  • 300 Pasteur Dr
    Stanford, CA 94305
    Phone: (650) 723-4000

Are you Dr. Sikic?

Claim your profile and join over 50% of U.S. physicians already on Doximity.

Claim this pageNo, this isn't me

Branimir Sikic, MD

Hematology Stanford, CA

Professor, Medicine - Oncology, Stanford University Medical Center

19 Colleague InvitesIs this you? Register Now to see 19 messages.

Summary

  • Dr. Branimir Sikic, MD is a board certified hematologist in Stanford, California. He is currently licensed to practice medicine in California. He is affiliated with Stanford Hospital and Clinics and Menlo Park Surgical Hospital.

Clinical Specialties & Interests

  • Hematology: General Hematology

Education & Training

  • Georgetown University HospitalGeorgetown University Hospital
  • University of Chicago Pritzker School of MedicineUniversity of Chicago Pritzker School of Medicine

Certifications & Licensure

  • CA State Medical LicenseCA State Medical License1979 - 2015
  • American Board of Internal MedicineMedical Oncology
  • American Board of Internal MedicineInternal Medicine

    Awards, Honors, & Recognition

    • Fellow (FASCO)American Society of Clinical Oncologists, 2010

    Clinical Trials

    Publications & Presentations

    PubMed

    Grant Support

    • Protocol Specific Research SupportNational Cancer Institute
      2010 - 2011
    • Taxane Resistance In Breast And Ovarian Cancer CellsNational Cancer Institute
      2007 - 2011
    • Study Of Oblimersen (Genasensetm, G3139) In Advanced MalignanciesNational Center For Research Resources
      2006 - 2006
    • Treatment Of Advanced Solid MalignanciesNational Center For Research Resources
      2005 - 2005
    • Study Of Oblimersen In Combination With Gemcitabine In Advanced MalignanciesNational Center For Research Resources
      2005 - 2005
    • A Phase I Study Of Oblimersen (Genasense TM, G3139)National Center For Research Resources
      2004 - 2004
    • Phase I Study: Weekly Bms-188797 Alone &With CarboplatNational Center For Research Resources
      2004 - 2004
    • Phase I Study Of Bms-310705 Given Every Three WeeksNational Center For Research Resources
      2004 - 2004
    • A Phase I Study Of ZD1839 (Iressa Tm) With OxaliplatinNational Center For Research Resources
      2004 - 2004
    • Regulation Of The Human MDR1 GeneNational Cancer Institute
      2002 - 2005
    • Gene Expression Profiling Of Unknown Primary CancersNational Cancer Institute
      2001 - 2003
    • Ly335979 &Mitoxantrone In Prostate CancerNational Center For Research Resources
      2000 - 2001
    • Phase I Trial Of Doxil, Paclitaxel And Valspodar PSC 833National Center For Research Resources
      2000 - 2001
    • Phase I Trial Of Oral Paclitaxel And Valspodar (Psc 833)National Center For Research Resources
      2000 - 2001
    • Modulation Of Multidrug Resistance MechanismsNational Cancer Institute
      1999 - 2002
    • Phase I Trial Of Antisense Inhibitor Of Protein Kinase C Alpha In CanNational Center For Research Resources
      1999 - 2001
    • CGP 64128a Administered As A Continuous Infusion In Patients With CancerNational Center For Research Resources
      1998 - 1999
    • Phase II Of ISIS 3521 In Patients With Ovarian CarcinomaNational Center For Research Resources
      1998 - 2001
    • Phase I Protein Kinase, Carboplatin And Paclitaxel Chemo. For CancerNational Center For Research Resources
      1998 - 2001
    • Paclitaxel And PSC 833 In Metastatic Colorectal CarcinomaNational Center For Research Resources
      1998 - 2001
    • Phase I Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources
      1997 - 2001
    • Phase I Clinical Trial Of Cgp64128a Administered As A Continuous InfusionNational Center For Research Resources
      1997 - 1997
    • Phase II Clinical Trial Of Paclitaxel &Psc 833 In Metastatic Colorectal CancerNational Center For Research Resources
      1997 - 1997
    • Tubulin Genes And Drug ResistanceNational Cancer Institute
      1996 - 1998
    • Trial Of Doxorubicin, Paclitaxel, And PSC 833National Center For Research Resources
      1996 - 1996
    • Phase 1 Trial Of Taxol And PSC-833 ChemotherapyNational Center For Research Resources
      1996 - 1996
    • Expression And Modulation Of Multidrug ResistanceNational Cancer Institute
      1990 - 1998
    • Cyano-Morpholino AnthracyclinesNational Cancer Institute
      1986 - 1988

    Hospital Affiliations

    Insurance Accepted

    • BCBS Blue Card PPO
    • BCBS California PPO
    • Blue Shield California PPO
    • CIGNA HMO
    • CIGNA Open Access
    • CIGNA PPO
    • First Health PPO
    • Great West PPO
    • Health Net California Large Group PPO
    • Multiplan PHCS PPO
    • Multiplan PHCS PPO - Kaiser
    • Multiplan PPO
    • United Healthcare - Direct Choice Plus POS
    • United Healthcare - Direct Options PPO

    Alternate Names

    • Dr. Branimir Sikic, Dr. Branimir Sikic, MD, Dr. B Sikic, Dr. Branimir I. Sikic

    Physicians, view Dr. Sikic's full Doximity profile to:

    • Trade HIPAA-secure messages
    • Send and receive online faxes
    • Refer a patient
    • See their complete CV